Low-dose oral microemulsion ciclosporin for severe, refractory ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 3, 2005, Pages 203-208

  De Saussure, P ^a,b   Soravia, C ^a   Morel, P ^a   Hadengue, A ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Hôpital Cantonal   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; C REACTIVE PROTEIN; CORTICOSTEROID; CREATININE; CYCLOSPORIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MICROEMULSION; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADULT; AGED; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; EMULSIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICROCHEMISTRY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 23844436649     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02552.x     Document Type: Article

References (34)

1. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1: 1067-70.
2. Truelove SC, Willoughby CP, Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978; 2: 1086-8.
3. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 1005-13.
4. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986; 27: 1210-2.
5. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-5.
6. Carbonnel F, Boruchowicz A, Duclos B, et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci 1996; 41: 2471-6.
7. Van Gossum A, Schmit A, Adler M, et al. Short- and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Belgian IBD Group. Acta Gastroenterol Belg 1997; 60: 197-200.
8. Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol 1998; 10: 411-3.
9. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94: 1587-92.
10. Rowe FA, Walker JH, Karp LC, Vasiliauskas EA, Plevy SE, Targan SR. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol 2000; 95: 2000-8.
11. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 10: 73-8.
12. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-9.
13. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-31.
14. Quan VA, Saunders BP, Hicks BH, Sladen GE. Cyclosporin treatment for ulcerative colitis complicated by fatal Pneumocystis carinii pneumonia. BMJ 1997; 314: 363-4.
15. Caroli A, Fregonese D, Di Falco G, D'Inca R. Aspergillus fumigatus pneumonia during cyclosporine treatment for ulcerative colitis. Am J Gastroenterol 2000; 95: 3016-7.
16. Vincent F, Bensousan TA. Cyclosporine in severe ulcerative colitis. N Engl J Med 1995; 332: 127.
17. Azoulay D, Lemoine A, Dennison A, et al. Incidence of adverse reactions to cyclosporine after liver transplantation is predicted by the first blood level. Hepatology 1993; 17: 1123-6.
18. Kovarik JM, Mueller EA, van Bree JB, Tetzloff W, Kutz K. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994; 83: 444-6.
19. Mueller EA, Kovarik JM, van Bree JB, Tetzloff W, Grevel J, Kutz K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994; 11: 301-4.
20. Haller GW, Winkler M, Bechstein WO, et al. Absorption of cyclosporine Neoral early after liver transplantation: is it possible to abandon intravenous cyclosporine A application? Transplant Proc 1996; 28: 2239-40.
21. Jirasiritham S, Sumethkul V, Mavichak V. Use of microemulsion form cyclosporine immediately after kidney transplantation without intravenous cyclosporine. Transplant Proc 1998; 30: 1760-1.
22. Actis GC, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis 1998; 4: 276-9.
23. Navazo L, Salata H, Morales S, et al. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcer ative and indeterminate colitis. Scand J Gastroenterol 2001; 36: 610-4.
24. Sood A, Midha V, Sood N. Oral cyclosporine in patients with active severe ulcerative colitis not responding to steroids. Indian J Gastroenterol 2002; 21: 155-6.
25. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041-8.
26. Sheth SG, LaMont JT. Toxic megacolon. Lancet 1998; 351: 509-13.
27. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000; 13: 313-26.
28. Kornbluth A. Is there still a role for cyclosporine in the treatment of inflammatory bowel disease? Pro argument. Inflamm Bowel Dis 2003; 9: 194-7; discussion 202-4.
29. Holt DW. Cyclosporin monitoring based on C2 sampling. Transplantation 2002; 73: 840-1.
30. Cantarovich M, Barkun J, Giannetti N, Cecere R, Besner JG, Tchervenkov J. History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion. Transplant Proc 2004; 36(Suppl. 2): 442S-7S.
31. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72: 1024-32.
32. Levy G, Burra P, Cavallari A, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation 2002; 73: 953-9.
33. Cantarovich M, Giannetti N, Cecere R. Impact of cyclosporine 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction. Clin Transplant 2003; 17: 144-50.
34. Latteri M, Angeloni G, Silveri NG, Manna R, Gasbarrini G, Navarra P. Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease. Clin Pharmacokinet 2001; 40: 473-83.